Susquehanna International Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Susquehanna International Group’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-87,300	Closed	-$1.76M	–	14378
2021 Q3	$1.76M	Buy	87,300 +20,700	+31%	+$571K	﹤0.01%	6124
2021 Q2	$2.49M	Sell	66,600 -48,200	-42%	-$1.48M	﹤0.01%	5430
2021 Q1	$2.94M	Buy	114,800 +42,800	+59%	+$1.09M	﹤0.01%	5022
2020 Q4	$1.59M	Sell	72,000 -184,500	-72%	-$4.06M	﹤0.01%	5605
2020 Q3	$4.61M	Buy	256,500 +222,700	+659%	+$4.61M	﹤0.01%	3159
2020 Q2	$859K	Buy	+33,800	New	+$728K	﹤0.01%	6245
2020 Q1	–	Sell	-98,200	Closed	-$2.16M	–	11166
2019 Q4	$2.16M	Buy	+98,200	New	+$1.98M	﹤0.01%	4196
2018 Q3	–	Sell	-70,700	Closed	-$866K	–	10591
2018 Q2	$866K	Sell	70,700 -53,600	-43%	-$673K	﹤0.01%	5661
2018 Q1	$1.19M	Buy	+124,300	New	+$1.34M	﹤0.01%	4896

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Susquehanna International Group's DRNA Position: Q4 2021 in Review

Susquehanna International Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 111,005 shares — an estimated $2.24M sold.

Susquehanna International Group first reported a position in DRNA in Q2 2016 and held it in 12 quarters. The position peaked at $5.7M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Susquehanna International Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Susquehanna International Group sold 111,005 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $2.24M.
Susquehanna International Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2016 and held it in 12 quarters.
Susquehanna International Group's Dicerna Pharmaceuticals, Inc. position peaked at $5.7M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.